Compound 2
“Compound 2” is a study-specific designation applied to different chemical entities in the biomedical literature rather than to one uniquely defined molecule.
“Compound 2” is a study-specific designation applied to different chemical entities in the biomedical literature rather than to one uniquely defined molecule. The reported examples include natural products isolated from fungi and plants, as well as synthetic medicinal-chemistry derivatives. In Talaromyces purpureogenus, compound 2 was reported to potentially arrest the cell cycle in S phase and trigger apoptosis. A compound assigned the same number from Excoecaria agallocha showed potent α-glucosidase inhibition, with an IC₅₀ of 0.11 μg/mL compared with 1.44 μg/mL for acarbose. Other studies used the designation for 14S-hydroxy-β-aflatrem from Aspergillus pseudonomius, a boronic acid-containing quinoxaline evaluated for boron delivery to MDA-MB-231 and HepG2 cells, and a lipoic-acid-containing thiazolo[5,4-d]pyrimidine designed as an A2A adenosine receptor antagonist.
Across the available literature, the designation therefore represents exploratory bioactive small-molecule discovery rather than a single established pharmaceutical target or mechanism. Related investigations include cytotoxicity, apoptosis, cell-cycle effects, α-glucosidase inhibition, boron accumulation relevant to boron neutron capture therapy, receptor antagonism, and cytoprotective screening against hypoxic kidney injury; one study reported nanomolar cytoprotective potency for compounds numbered 2 and 6. These findings place “Compound 2” within a broad discovery landscape involving cancer, autophagy, oxidative stress, and molecular-target-directed chemical synthesis, but they do not establish a unified pharmacological profile.
Where the papers sit
8 papers from the last 6 months study compound 2 directly · updated from PubMed 27 Oct 2026
Study type 0 clinical trials · 8 preclinical
Themes one subject
Those 8 are all about one subject.
-
Bioactive Small-Molecule Discovery
Natural products and designed small molecules are being explored as sources of new bioactive agents. Cytotoxicity, antiproliferative activity and disease-relevant pathway modulation recur across the studies. The work spans autotaxin, CCN1, A2A adenosine receptors and boron delivery, alongside structural elucidation of diverse metabolites. No single disease, target or mechanism dominates, leaving target validation and therapeutic selectivity as open questions.
Papers
The 8 papers from the last 6 months that study compound 2 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Bioactive Small-Molecule Discovery (8)
- Identification of New Putative Autotaxin Inhibitors via Structure-Based Virtual Screening and Evaluation of Their Antiproliferative Properties Against Ovarian and Breast Cancer Cells. ChemMedChem · 1 Sept 2026 PMID 42675576
- Exolide A, structurally diverse Ent-18-norbeyerane diterpenoid from the stems of Indian mangrove plant, Excoecaria agallocha Linn. Fitoterapia · 29 Aug 2026 PMID 42668099
- Discovery of Monoterpenoid Indole Alkaloids Targeting CCN1 to Suppress Autophagy for the Treatment of Hypoxic Kidney Injury. Journal of medicinal chemistry · 23 Aug 2026 PMID 42632911
- Cytotoxic sesquiterpene alkaloids isolated from Nuphar pumila (Timm) de Candolle. Fitoterapia · 1 Aug 2026 PMID 42542302
- Cytotoxic indole diterpenoids from the fungus Aspergillus pseudonomius: isolation, structural elucidation, and biological evaluation. Bioorganic chemistry · 6 Jul 2026 PMID 42407346
- Design, synthesis, and pharmacological evaluation of thiazolo[5,4-d]pyrimidines hybridized with lipoic acid or catechol. Novel A2A adenosine receptor antagonists in neuroinflammatory diseases. Bioorganic chemistry · 26 Jun 2026 PMID 42361677
- Design, synthesis and biological evaluation of boronic acid-containing quinoxaline derivatives as potential boron carriers for boron neutron capture therapy. Bioorganic chemistry · 17 Jun 2026 PMID 42308785
- Cytotoxic spirocyclic polyketides and γ-lactones from endophytic fungus Talaromyces purpureogenus Y21 guided by molecular networking and SMART strategies. Phytochemistry · 21 May 2026 PMID 42167708
By study type
Preclinical: animal, cell and lab studies (8)
- Identification of New Putative Autotaxin Inhibitors via Structure-Based Virtual Screening and Evaluation of Their Antiproliferative Properties Against Ovarian and Breast Cancer Cells. ChemMedChem · 1 Sept 2026 PMID 42675576
- Exolide A, structurally diverse Ent-18-norbeyerane diterpenoid from the stems of Indian mangrove plant, Excoecaria agallocha Linn. Fitoterapia · 29 Aug 2026 PMID 42668099
- Discovery of Monoterpenoid Indole Alkaloids Targeting CCN1 to Suppress Autophagy for the Treatment of Hypoxic Kidney Injury. Journal of medicinal chemistry · 23 Aug 2026 PMID 42632911
- Cytotoxic sesquiterpene alkaloids isolated from Nuphar pumila (Timm) de Candolle. Fitoterapia · 1 Aug 2026 PMID 42542302
- Cytotoxic indole diterpenoids from the fungus Aspergillus pseudonomius: isolation, structural elucidation, and biological evaluation. Bioorganic chemistry · 6 Jul 2026 PMID 42407346
- Design, synthesis, and pharmacological evaluation of thiazolo[5,4-d]pyrimidines hybridized with lipoic acid or catechol. Novel A2A adenosine receptor antagonists in neuroinflammatory diseases. Bioorganic chemistry · 26 Jun 2026 PMID 42361677
- Design, synthesis and biological evaluation of boronic acid-containing quinoxaline derivatives as potential boron carriers for boron neutron capture therapy. Bioorganic chemistry · 17 Jun 2026 PMID 42308785
- Cytotoxic spirocyclic polyketides and γ-lactones from endophytic fungus Talaromyces purpureogenus Y21 guided by molecular networking and SMART strategies. Phytochemistry · 21 May 2026 PMID 42167708
Written from 8 PubMed abstracts, each one listed by PMID above. Published: 2026-10-27. Drafted by language models from published abstracts; not medical advice.